- Email: [email protected]
4920048 Method for stabilizing extra-chromosomal elements in bacteria during cultivation
PATENT ABSTRACTS
4918006 GENE CODING FOR INSECTICIDAL CRYSTAL PROTEIN David J Ellar, Elizabeth S Ward, Kingston, United Kingdom assigned to E I Du Pont de Nemours and Company Recombinant plasmids containing the larvicidal delta-endotoxin gene were constructed by inserting HindlII fragments of the Bacillus thuringiensis var. israelensis 72-75 Md plasmid into the Escherichia coli vector pUCI2. Two recombinants producing a 27-kdal toxin (plP173 and pIP174) were indentified by screening clones in an E. coli in vitro transcription-translation system. Both recombinants comprised pUCI2 and common 9.7 kb HindlII fragment of the B. thuringiensis plasmid. The 27, 340 Da polypeptide synthesized in vito from piP174 transformed into E. coli JM101 and from B. subtilis 168 and spoOJ87 containing the 1.2 kb TaqI fragment from plP173 was lethal to mosquito larvae.
6ol
4918166 PARTICULATE HYBRID ANTIGENS
HIV
Alan J Kingsman, Susan M Kingsman, Sally E Adams, Islip, United Kingdom assigned to Oxford Gene Systems Limited Fusion proteins comprise a77 first amino acid sequence and a second amino acid sequence. The first amino acid sequence is derived from a retrotransposon or an RNA retrovirus and confers on the fusion protein the ability to assemble into particles; an example is the product of the YTA gene of the yeast retrotransposon Ty. The second amino acid sequence is an HIV antigen. So particles formed of the fusion proteins may be useful in vaccines or in diagnostic or purification applications.
4918178 TEST FOR JOHNE'S
DISEASE
Sarah S Hurley, Gary A Splitter, Rodney A Welch assigned to Wisconsin Alumni Research Foundation
~1~15 GENTAMICIN-RESISTANCE GENES AND THEIR USE AS MARKERS
A test to diagnose the presence of Johne's disease is disclosed. In one aspect it involves using a D N A segment that will hybridize to M. paratuberculosis but not to other bacteria typically found in bovine feces. Another aspect of the invention is providing a process for breaking the cell wall of mycobacteria using dense beads in the presence of phenol.
Wolfgang Wohlleben, Gunte Muth, Alfred Puhler, Bielefeld, Federal Republic Of Germany assigned to Hoechst Aktiengesellschaft S. ghanaensis DSM 2932 is resistant to gentamicin at up to 20 mug/ml. Total digestion of the genomic D N A with Bglll, incorporation of the restriction fragments into a suitable plasmid, and selection using gentamicin results in gentamicin-resistant clones which contain a 7 kb fragment with the gentamicin-resistance gene. The plasmid pPHIJI likewise contains a gentamicin-l"esistance gene located on a 2.3 kb HindlII-BamHI fragment. These genes are suitable as markers, in particular for Streptomycetes vectors.
4920048 METHOD FOR STABILIZING EXTRA-CHROMOSOMAL ELEMENTS IN BACTERIA DURING CULTIVATION Borge K Diderichsen, Hellerup, Denmark assigned to Novo Industri A/S A method for stabilization of extrachromosomal elements in bacteria during cul-
PATENT ABSTRACTS
602
tivation which comprises transformation of a host bacterium having a defect in a chromosomal gene needed for the synthesis or maintenance of the cell envelope with an extrachromosomal element capable of complementing the chromosomal gene defect of the host bacterium, the extra-chromosomal element also including an expressible DNA-sequenee coding for a desired product.
4920054 SHUTTLE VECTORS FROM RHODOCOCCUS EQUI Maya Kozlowski, Wayne Glasse-Davies, Brampton, Canada assigned to Allelix Inc Recombinant D N A plasmids capable of functioning as shuttle vectors in Rhodococcus equi, Corynebacterium, E. coli, B. subtilis, or S. aureus are disclosed. The recombinant plasmid contains an origin of replication which is functional in Rhodococcus and at least one of E. coil, Corynebacterium, S. aureus, and B. subtilis. Additionally, the plasmid contains a heritable, selectable marker.
A functional mutated E1A gene of human adenovirus subgroup B: ! is provided which has a modified autorepression functional domain that is effective to express EIA products that stimulate without net repression of promoters controlling an EIA mutated gene.
4920213 METHOD AND COMPOSITIONS USEFUL IN PREVENTING EQUINE INFLUENZA Beverl Dale, Barbara Cordell assigned to Biotechnology Research Partners Ltd Recombinant vaccines for immunizing horses against equine influenza virus (EIV) are disclosed. The DNA sequences encoding the hemagglutinin (HA) and neuraminidase (NA) glycoproteins from the two strains of EIV currently infective in horses are used to construct vaccinia carried vaccines, to design synthetic peptides for primer and booster administration, and to permit recombinant synthesis of HA and/or NA protein based vaccines. These DNA sequences also provide probes useful for preparing similar vaccines from fresh isolates of new strains generated by genetic drift.
4920209 ORAL VACCINES Alan R Davis, Paul P Hung assigned to American Home Products Corporation Methods and vaccines for the production of antibodies to infectious organisms are described. Live recombinant adenovirus containing a foreign gene coding for an antigen produced by another infectious organism is delivered to the intestine of a warm-blooded animal in an enteric-coated dosage form, whereupon the virus infects the gut wall and induces the production of antibodies or cell mediated immunity to both adenovirus and the other infectious organism.
4920211 MUTATED ADENOVIRUS EIA GENE FOR E1A PROMOTER STIMULATION Clark Tibbetts, Pamela L Larsen assigned to Vanderbilt University
4921757 SYSTEM FOR DELAYED AND PULSED RELEASE OF BIOLOGICALLY ACTIVE SUBSTANCES Margaret Whcatley, Robert Langer, Herman Eisen assigned to Massachusetts Institute of Technology A system for controlled release both in vivo and in vitro of entrapped substances, either at a constant rate over a period of time or in discrete pulses, is disclosed. Biologically active substances, such as drugs, hormones, enzymes, genetic material, antigens including viruses, vaccines, or inorganic material such as dyes and nutrients, are entrapped in liposomes which are protected from the biological environment by encapsulation within semi-permeable microcapsules or a permeable polymeric matrix. Release of the entrapped substance into the surrounding environment is governed by the permeability of both the liposome and surrounding matrix to the substance. Permeability of the lipo-
4918006 GENE CODING FOR INSECTICIDAL CRYSTAL PROTEIN David J Ellar, Elizabeth S Ward, Kingston, United Kingdom assigned to E I Du Pont de Nemours and Company Recombinant plasmids containing the larvicidal delta-endotoxin gene were constructed by inserting HindlII fragments of the Bacillus thuringiensis var. israelensis 72-75 Md plasmid into the Escherichia coli vector pUCI2. Two recombinants producing a 27-kdal toxin (plP173 and pIP174) were indentified by screening clones in an E. coli in vitro transcription-translation system. Both recombinants comprised pUCI2 and common 9.7 kb HindlII fragment of the B. thuringiensis plasmid. The 27, 340 Da polypeptide synthesized in vito from piP174 transformed into E. coli JM101 and from B. subtilis 168 and spoOJ87 containing the 1.2 kb TaqI fragment from plP173 was lethal to mosquito larvae.
6ol
4918166 PARTICULATE HYBRID ANTIGENS
HIV
Alan J Kingsman, Susan M Kingsman, Sally E Adams, Islip, United Kingdom assigned to Oxford Gene Systems Limited Fusion proteins comprise a77 first amino acid sequence and a second amino acid sequence. The first amino acid sequence is derived from a retrotransposon or an RNA retrovirus and confers on the fusion protein the ability to assemble into particles; an example is the product of the YTA gene of the yeast retrotransposon Ty. The second amino acid sequence is an HIV antigen. So particles formed of the fusion proteins may be useful in vaccines or in diagnostic or purification applications.
4918178 TEST FOR JOHNE'S
DISEASE
Sarah S Hurley, Gary A Splitter, Rodney A Welch assigned to Wisconsin Alumni Research Foundation
~1~15 GENTAMICIN-RESISTANCE GENES AND THEIR USE AS MARKERS
A test to diagnose the presence of Johne's disease is disclosed. In one aspect it involves using a D N A segment that will hybridize to M. paratuberculosis but not to other bacteria typically found in bovine feces. Another aspect of the invention is providing a process for breaking the cell wall of mycobacteria using dense beads in the presence of phenol.
Wolfgang Wohlleben, Gunte Muth, Alfred Puhler, Bielefeld, Federal Republic Of Germany assigned to Hoechst Aktiengesellschaft S. ghanaensis DSM 2932 is resistant to gentamicin at up to 20 mug/ml. Total digestion of the genomic D N A with Bglll, incorporation of the restriction fragments into a suitable plasmid, and selection using gentamicin results in gentamicin-resistant clones which contain a 7 kb fragment with the gentamicin-resistance gene. The plasmid pPHIJI likewise contains a gentamicin-l"esistance gene located on a 2.3 kb HindlII-BamHI fragment. These genes are suitable as markers, in particular for Streptomycetes vectors.
4920048 METHOD FOR STABILIZING EXTRA-CHROMOSOMAL ELEMENTS IN BACTERIA DURING CULTIVATION Borge K Diderichsen, Hellerup, Denmark assigned to Novo Industri A/S A method for stabilization of extrachromosomal elements in bacteria during cul-
PATENT ABSTRACTS
602
tivation which comprises transformation of a host bacterium having a defect in a chromosomal gene needed for the synthesis or maintenance of the cell envelope with an extrachromosomal element capable of complementing the chromosomal gene defect of the host bacterium, the extra-chromosomal element also including an expressible DNA-sequenee coding for a desired product.
4920054 SHUTTLE VECTORS FROM RHODOCOCCUS EQUI Maya Kozlowski, Wayne Glasse-Davies, Brampton, Canada assigned to Allelix Inc Recombinant D N A plasmids capable of functioning as shuttle vectors in Rhodococcus equi, Corynebacterium, E. coli, B. subtilis, or S. aureus are disclosed. The recombinant plasmid contains an origin of replication which is functional in Rhodococcus and at least one of E. coil, Corynebacterium, S. aureus, and B. subtilis. Additionally, the plasmid contains a heritable, selectable marker.
A functional mutated E1A gene of human adenovirus subgroup B: ! is provided which has a modified autorepression functional domain that is effective to express EIA products that stimulate without net repression of promoters controlling an EIA mutated gene.
4920213 METHOD AND COMPOSITIONS USEFUL IN PREVENTING EQUINE INFLUENZA Beverl Dale, Barbara Cordell assigned to Biotechnology Research Partners Ltd Recombinant vaccines for immunizing horses against equine influenza virus (EIV) are disclosed. The DNA sequences encoding the hemagglutinin (HA) and neuraminidase (NA) glycoproteins from the two strains of EIV currently infective in horses are used to construct vaccinia carried vaccines, to design synthetic peptides for primer and booster administration, and to permit recombinant synthesis of HA and/or NA protein based vaccines. These DNA sequences also provide probes useful for preparing similar vaccines from fresh isolates of new strains generated by genetic drift.
4920209 ORAL VACCINES Alan R Davis, Paul P Hung assigned to American Home Products Corporation Methods and vaccines for the production of antibodies to infectious organisms are described. Live recombinant adenovirus containing a foreign gene coding for an antigen produced by another infectious organism is delivered to the intestine of a warm-blooded animal in an enteric-coated dosage form, whereupon the virus infects the gut wall and induces the production of antibodies or cell mediated immunity to both adenovirus and the other infectious organism.
4920211 MUTATED ADENOVIRUS EIA GENE FOR E1A PROMOTER STIMULATION Clark Tibbetts, Pamela L Larsen assigned to Vanderbilt University
4921757 SYSTEM FOR DELAYED AND PULSED RELEASE OF BIOLOGICALLY ACTIVE SUBSTANCES Margaret Whcatley, Robert Langer, Herman Eisen assigned to Massachusetts Institute of Technology A system for controlled release both in vivo and in vitro of entrapped substances, either at a constant rate over a period of time or in discrete pulses, is disclosed. Biologically active substances, such as drugs, hormones, enzymes, genetic material, antigens including viruses, vaccines, or inorganic material such as dyes and nutrients, are entrapped in liposomes which are protected from the biological environment by encapsulation within semi-permeable microcapsules or a permeable polymeric matrix. Release of the entrapped substance into the surrounding environment is governed by the permeability of both the liposome and surrounding matrix to the substance. Permeability of the lipo-